228 related articles for article (PubMed ID: 18564357)
1. High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils.
Almeida CB; Traina F; Lanaro C; Canalli AA; Saad ST; Costa FF; Conran N
Br J Haematol; 2008 Sep; 142(5):836-44. PubMed ID: 18564357
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.
Kleiman RJ; Chapin DS; Christoffersen C; Freeman J; Fonseca KR; Geoghegan KF; Grimwood S; Guanowsky V; Hajós M; Harms JF; Helal CJ; Hoffmann WE; Kocan GP; Majchrzak MJ; McGinnis D; McLean S; Menniti FS; Nelson F; Roof R; Schmidt AW; Seymour PA; Stephenson DT; Tingley FD; Vanase-Frawley M; Verhoest PR; Schmidt CJ
J Pharmacol Exp Ther; 2012 May; 341(2):396-409. PubMed ID: 22328573
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.
Almeida CB; Scheiermann C; Jang JE; Prophete C; Costa FF; Conran N; Frenette PS
Blood; 2012 Oct; 120(14):2879-88. PubMed ID: 22833547
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants.
Wang P; Wu P; Egan RW; Billah MM
Gene; 2003 Sep; 314():15-27. PubMed ID: 14527714
[TBL] [Abstract][Full Text] [Related]
5. Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation.
Canalli AA; Franco-Penteado CF; Saad ST; Conran N; Costa FF
Haematologica; 2008 Apr; 93(4):605-9. PubMed ID: 18326523
[TBL] [Abstract][Full Text] [Related]
6. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T
Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659
[TBL] [Abstract][Full Text] [Related]
7. Role for cAMP-protein kinase A signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease.
Canalli AA; Franco-Penteado CF; Traina F; Saad ST; Costa FF; Conran N
Eur J Haematol; 2007 Oct; 79(4):330-7. PubMed ID: 17680813
[TBL] [Abstract][Full Text] [Related]
8. Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties.
Gambero S; Canalli AA; Traina F; Albuquerque DM; Saad ST; Costa FF; Conran N
Eur J Haematol; 2007 Feb; 78(2):144-51. PubMed ID: 17313560
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of caspase-dependent spontaneous apoptosis via a cAMP-protein kinase A dependent pathway in neutrophils from sickle cell disease patients.
Conran N; Almeida CB; Lanaro C; Ferreira RP; Traina F; Saad ST; Costa FF
Br J Haematol; 2007 Oct; 139(1):148-58. PubMed ID: 17711515
[TBL] [Abstract][Full Text] [Related]
10. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy.
Lanaro C; Franco-Penteado CF; Albuqueque DM; Saad ST; Conran N; Costa FF
J Leukoc Biol; 2009 Feb; 85(2):235-42. PubMed ID: 19004988
[TBL] [Abstract][Full Text] [Related]
11. [Modern representations of multiple forms of cyclic nucleotide phosphodiesterases in mammalian tissues].
Medvedeva MV
Biokhimiia; 1995 Mar; 60(3):364-86. PubMed ID: 7734612
[TBL] [Abstract][Full Text] [Related]
12. C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling.
Wang PX; Li ZM; Cai SD; Li JY; He P; Huang Y; Feng GS; Luo HB; Chen SR; Liu PQ
Acta Pharmacol Sin; 2017 Sep; 38(9):1257-1268. PubMed ID: 28649129
[TBL] [Abstract][Full Text] [Related]
13. Dual roles of PDE9a in meiotic maturation of zebrafish oocytes.
Li J; Bai L; Liu Z; Wang W
Biochem Biophys Res Commun; 2020 Oct; 532(1):40-46. PubMed ID: 32826058
[TBL] [Abstract][Full Text] [Related]
14. [Phosphodiesterases of cyclic GMP].
Wróblewska H; Gorczyca WA
Postepy Hig Med Dosw; 2001; 55(5):611-27. PubMed ID: 11795198
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase 9: insights from protein structure and role in therapeutics.
Singh N; Patra S
Life Sci; 2014 Jun; 106(1-2):1-11. PubMed ID: 24746902
[TBL] [Abstract][Full Text] [Related]
16. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
Kass DA
Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
[No Abstract] [Full Text] [Related]
17. Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals.
Miguel LI; Almeida CB; Traina F; Canalli AA; Dominical VM; Saad ST; Costa FF; Conran N
Inflamm Res; 2011 Jul; 60(7):633-42. PubMed ID: 21336703
[TBL] [Abstract][Full Text] [Related]
18. The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in Rodents.
Rosenbrock H; Giovannini R; Schänzle G; Koros E; Runge F; Fuchs H; Marti A; Reymann KG; Schröder UH; Fedele E; Dorner-Ciossek C
J Pharmacol Exp Ther; 2019 Dec; 371(3):633-641. PubMed ID: 31578258
[No Abstract] [Full Text] [Related]
19. Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients.
Conran N; Oresco-Santos C; Acosta HC; Fattori A; Saad ST; Costa FF
Br J Haematol; 2004 Feb; 124(4):547-54. PubMed ID: 14984506
[TBL] [Abstract][Full Text] [Related]
20. PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition.
Kroker KS; Mathis C; Marti A; Cassel JC; Rosenbrock H; Dorner-Ciossek C
Neurobiol Aging; 2014 Sep; 35(9):2072-8. PubMed ID: 24746365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
